Page 127 - 《中国药房》2025年7期

[11] NATARAJAN V，DUDEK S M，JACOBSON J R，et al. macokinetics and pharmacodynamics of ozanimod in ul‐
Sphingosine-1-phosphate，FTY720，and sphingosine-1- cerative colitis[J]. Inflamm Bowel Dis，2022，28（Suppl.
phosphate receptors in the pathobiology of acute lung in‐ 1）：S16.
jury[J]. Am J Respir Cell Mol Biol，2013，49（1）：6-17. [24] AYOUB M，MATTAY S，YARUR A J，et al. Managing
[12] OLESCH C，SIRAIT-FISCHER E，BERKEFELD M， risks with newer oral small molecules in patients with in‐
et al. S1PR4 ablation reduces tumor growth and improves flammatory bowel diseases[J]. Curr Gastroenterol Rep，
chemotherapy via CD8 T cell expansion[J]. J Clin Invest， 2024，26（5）：145-156.
+
2020，130（10）：5461-5476. [25] SANDBORN W J，FEAGAN B G，HANAUER S，et al.
[13] NARULA N，KASSAM Z，YUAN Y H，et al. Systematic Long-term efficacy and safety of ozanimod in moderately
review and meta-analysis：fecal microbiota transplantation to severely active ulcerative colitis：results from the open-
for treatment of active ulcerative colitis[J]. Inflamm label extension of the randomized， phase 2
Bowel Dis，2017，23（10）：1702-1709. TOUCHSTONE study[J]. J Crohns Colitis，2021，15（7）：
[14] ZHANG K，GUO J，YAN W L，et al. Macrophage polari- 1120-1129.
zation in inflammatory bowel disease[J]. Cell Commun [26] CHOI D，STEWART A P，BHAT S. Ozanimod：a first-in-
Signal，2023，21（1）：367. class sphingosine 1-phosphate receptor modulator for the
[15] TOURKOCHRISTOU E，MOUZAKI A，TRIANTOS C. treatment of ulcerative colitis[J]. Ann Pharmacother，
Unveiling the biological role of sphingosine-1-phosphate 2022，56（5）：592-599.
receptor modulators in inflammatory bowel diseases[J]. [27] SANDBORN W J，FEAGAN B G，HAENS G，et al. Oza‐
World J Gastroenterol，2023，29（1）：110-125. nimod as induction and maintenance therapy for ulcera-
[16] PANÉS J，SALAS A. Past，present and future of therapeu‐ tive colitis[J]. N Engl J Med，2021，385（14）：1280-1291.
tic interventions targeting leukocyte trafficking in inflam‐ [28] WILLIAM S，GEERT D，DOUG W，et al. P025 ozanimod
matory bowel disease[J]. J Crohns Colitis，2018，12 efficacy，safety，and histology in patients with moderate-
（Suppl. 2）：S633-S640. to-severe ulcerative colitis during induction in the phase 3
[17] MCGINLEY M P，COHEN J A. Sphingosine 1-phosphate true north study[J]. Am J Gastroenterol，2020，115（Suppl.
receptor modulators in multiple sclerosis and other condi‐ 1）：S6-S7.
tions[J]. Lancet，2021，398（10306）：1184-1194. [29] D’AMICO F，ALLOCCA M，FIORINO G. Positioning
[18] CHEN T Z，GU K E，LIN R Y，et al. The function of ozanimod in ulcerative colitis：restoring leukocyte traffic
Sphingosine-1-phosphate receptor 2（S1PR2） in maintaining under control[J]. Gastroenterology，2022，162（6）：1767-
intestinal barrier and inducing ulcerative colitis[J]. Bioen‐ 1769.
gineered，2022，13（5）：13703-13717. [30] WILS P，PEYRIN-BIROULET L. Etrasimod for the treat‐
[19] FAN X H，LIU L L，SHI Y，et al. Recent advances of the ment of ulcerative colitis[J]. Immunotherapy，2023，15
function of sphingosine 1-phosphate （S1P） receptor S1P3 （5）：311-321.
[J]. J Cell Physiol，2021，236（3）：1564-1578. [31] AL-SHAMMA H，LEHMANN-BRUINSMA K，CARROLL
[20] OLESCH C，RINGEL C，BRÜNE B，et al. Beyond im‐ C，et al. The selective sphingosine 1-phosphate receptor
mune cell migration：the emerging role of the sphingosine- modulator etrasimod regulates lymphocyte trafficking and
1-phosphate receptor S1PR4 as a modulator of innate im‐ alleviates experimental colitis[J]. J Pharmacol Exp Ther，
mune cell activation[J]. Mediators Inflamm，2017，2017： 2019，369（3）：311-317.
6059203. [32] KIYOMI K，CAROLINE L，LISETTE A，et al. Effect of
[21] SCOTT F L，CLEMONS B，BROOKS J，et al. Ozanimod etrasimod on circulating lymphocyte subsets：data from a
（RPC1063） is a potent sphingosine-1-phosphate receptor- randomized phase 1 study in healthy Japanese and Cauca‐
1 （S1P1） and receptor-5 （S1P5） agonist with autoim‐ sian men[J]. Am J Gastroenterol，2020，115（Suppl. 1）：
mune disease-modifying activity[J]. Br J Pharmacol， S12.
2016，173（11）：1778-1792. [33] GRAS J. Etrasimod arginine[J]. Drugs of the Future，
[22] PAIK J. Ozanimod：a review in ulcerative colitis[J]. 2020，45（3）：165-73.
Drugs，2022，82（12）：1303-1313. [34] YARUR A J，CHIOREAN M V，PANÉS J，et al. Achieve‐
[23] TATOSIAN D，SHEN J，CHEN L，et al. Population phar‐ ment of clinical，endoscopic，and histological outcomes in

中国药房 2025年第36卷第7期 China Pharmacy 2025 Vol. 36 No. 7 · 885 ·